Myongji Hospital is accelerating its efforts to become a biomedical hub hospital by enhancing advanced research and development in partnership with Bionsystems, a bio-drug developer.

Under the business agreement, the two sides will promote joint R&D and technology exchange, support the commercialization of medical R&D, joint use of equipment and facilities, exchange of R&D personnel, jointly host international conferences and seminars, academic conferences, technology development, quality improvement, and business promotion for clinical trials, according to Myongji Hospital.

“At stake is how to develop a biomedical model that will lead the Fourth Industrial Revolution and future strategy through collaborations between medical institutions that have strong credentials in clinical and research fields and bio companies that serve as platforms to commercialize developed substances,” Myongji Hospital President Kim Jin-goo said. “We will work with Bionsystems to create a successful real case of open innovation that utilizes each other’s characteristics and strengths.”

Bionsystems CEO Kim Jong-yoon said, “Through close cooperation with Myongji Hospital, which is building an innovative research-oriented hospital model, we hope to become a leader in R&D in the biomedical field based on a big data-based drug discovery, a long-acting Fc, and a biopharmaceutical analysis platform.”

Bionsystems is researching the next-generation antibody fusion protein based on big data and know-how accumulated for more than 10 years of biopharmaceutical analysis.

It is also developing innovative therapeutics in immunotherapy, autoimmune diseases, and asthma.